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Abstract  
The anoxemia theory proposes that an imbalance between the demand for, and supply of, oxygen in the 
arterial wall is a key factor in the development of atherosclerosis. There is now substantial evidence 
that there are regions within the atherosclerotic plaque in which profound hypoxia exists; this may 
fundamentally change the function, metabolism and responses of many of the cell types found within 
the developing plaque and whether the plaque will evolve into a stable or unstable phenotype. Hypoxia 
is characterized in molecular terms by the stabilization of hypoxia inducible factor (HIF)-1α; a subunit 
of the hetero-dimeric nuclear transcriptional factor HIF-1; a master regulator of oxygen homeostasis. 
HIF-1 expression is localized to perivascular tissues, inflammatory macrophages and smooth muscle 
cells adjacent to the necrotic core of atherosclerotic lesions, and regulates several genes that are 
important to vascular function including vascular endothelial growth factor (VEGF), nitric oxide 
synthase (NOS), endothelin-1 and erythropoietin (EPO). This review summarizes the effects of hypoxia 
on the functions of cells involved in atherogenesis, and the evidence for its potential importance from 
experimental models and clinical studies. 
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Introduction 
Atherosclerosis is a chronic inflammatory process, affecting medium and large arteries, and involving 
lipid deposition, oxidative stress, endothelial damage, and smooth muscle cell proliferation and 
migration. It is associated with several established risk factors, including: hypertension, 
hyperglycaemia, aging and dyslipidaemia.1 There have been a number of hypotheses of atherogenesis, 
including the anoxemia theory that proposes that an imbalance between the demand for and supply of 
oxygen in the arterial wall is a key factor in the development of atherosclerosis.2, 3 The micro-
environment within the atherosclerotic plaque is thought to be an important determinant of whether a 
plaque progresses, and the likelihood of clinical complications. It has previously been difficult to 
investigate cellular metabolism within the artery wall with sufficiently high resolution, and 
consequently it has not been possible to identify regions in which extreme hypoxia prevails. However, 
recent reports do provide substantial evidence that there are regions within the plaque in which hypoxia 
can be identified.4 This state of hypoxia has the potential to fundamentally change the function, 
metabolism and responses of many of the cell types found within the developing atherosclerotic plaque, 
and this may in turn determine whether the plaque evolves into a stable or unstable phenotype. It is 
likely that this is mediated through effects on angiogenesis, extracellular matrix elaboration and 
lipoprotein metabolism. The hypoxic milieu in the atherosclerotic plaque may therefore also have 
implications for the putative therapeutic interventions for atherosclerosis. However, most in vitro 
studies have been conducted under normoxic conditions. The effects observed under these conditions 
may not accurately reflect those extant within the plaque. 
The Development of a Hypoxic environment within the Atherosclerotic Plaque 
Hypoxia may be defined as a physiological or pathological state in which the body, or a region of the 
body, is deprived of adequate oxygen supply at the tissue level to an extent that it is inadequate to meet 
cellular, or tissue demands. Hypoxia may be due to a reduced oxygen supply (due to insufficient blood 
vessel network or defects in blood vessels) or to an increased consumption of oxygen relative to the 
supply (this may result from a rapid increase in cell proliferation). It is usually characterized in 
molecular terms by the stabilization of hypoxia inducible factor (HIF)-1α; a subunit of the heterodimeric 
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nuclear transcriptional factor HIF-1. HIF-1, consisting of HIF-1α and HIF-1β subunits, has been 
described as a master regulator of oxygen homeostasis. Whilst levels of HIF-1α have been shown to be 
regulated by non-hypoxic stimuli such as lipopolysaccharides (LPS), thrombin, and angiotensin II (Ang 
II),5 it is generally considered to be a biological marker of hypoxia and drives the expression of over 
100 genes including those involved in angiogenesis and oxygen transport.6 (see Figure 1 7). There are, 
however, some circumstances under which HIF-1α expression can be prevented.8 Hypoxia also 
stabilises HIF-2α which is closely related to HIF-1α with respect to its involvement in the transcriptional 
activation of multiple target genes in hypoxia.9 
In studies using human artery specimens and tissues from experimental animal models of 
atherosclerosis, HIF-1α has been localized to perivascular tissues, inflammatory macrophages and 
smooth muscle cells adjacent to the necrotic core of atherosclerotic lesions. In addition to being a marker 
of hypoxia, HIF-1α may directly enhance atherogenesis through several mechanisms, including: smooth 
muscle cell proliferation and migration, new vessel formation (angiogenesis), and altered lipid 
metabolism. Alteration of the HIF-1α pathway has been shown to contribute to vascular graft failure 
through the formation of intimal hyperplasia in which smooth muscle cells from the tunica media (the 
main muscle layer of the graft vessel) migrate to, and proliferate within what is termed the neo-intima.10 
HIF-1α has also been implicated in the pathogenesis of atherosclerosis, in-stent restenosis following 
coronary re-vascularisation, stroke, peripheral artery disease, aortic aneurysm formation and pulmonary 
artery hypertension 11, and also appears to be involved in the calcification of blood vessels, which often 
accompanies atherosclerosis. For example, Li et al have shown that in diabetic patients with a high 
coronary artery calcium (CAC) score, serum HIF-1α levels were significantly raised, and were an 
independent risk factor for the presence of CAC. Serum HIF-1α levels were positively correlated with 
other biomarkers of diabetic control and inflammation, such as C-reactive protein (CRP), Interleulin-6 
(IL-6), HbA1c, fasting blood glucose (FBG), and CAC score. HIF-1α levels were therefore considered 
to be a significant independent risk factor, predicting the presence of CAC.12 Whilst HIF-1 is an 
intracellular transcription factor, it is possible that it is released into the circulation from damaged cells, 
as has been reported for other transcriptional factors that include NF-κB and p53.12-14 In healthy medium 
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sized arteries, the tunica intima (the innermost layer of the artery wall), is a delicate layer consisting of 
the endothelium, extracellular matrix, and a basement membrane comprising the internal elastic lamina 
(Figure 2a). During atherogenesis, the intima may thicken by the accumulation of cells and matrix, and 
the diffusion of oxygen can then become impaired (Figure 2b). Vasa vasorum form a network of small 
blood vessels lying within the tunica adventitia (the outermost layer of the artery wall). These vessels 
provide oxygen and nutrients to the wall of the artery. Vasa vasorum are vulnerable to hypoxia 
especially at the site of arterial branching as they are end arteries and the blood flow is reduced in this 
region. It has been hypothesized that hypoxia within the vasa vasorum is due to reduced blood flow and 
consequent endothelial dysfunction, local inflammation and permeation of large particles such as 
microbes, LDL-lipoprotein and fatty acids which are transformed by macrophages into foam cells 15, 16, 
which may be an initiating factor in atherosclerosis. The majority of inflammatory cells contributing to 
early atherosclerosis, probably enter the artery wall from the lumen, as shown by the elegant studies of 
Ross and colleagues.17, 18 However, the vasa vasorum and associated micro-vessels may provide an 
alternate route by which leucocytes can enter the vascular wall.19 As atherosclerosis progresses, 
angiogenic factors within the micro-environment of the plaque may stimulate new vessel formation. 
The combination of this delicate network of new vessels in juxtaposition to regions rich in inflammatory 
cells, that elaborate proteolytic enzymes, may contribute to intra-plaque haemorrhage and subsequent 
plaque rupture.20 The involvement of vasa vasorum and intimal hyperplasia in the pathophysiology of 
atherosclerosis is supported by several experimental animal studies.21, 22 
Evidence for Hypoxia within Atherosclerotic Plaque 
The partial pressure of oxygen (pO2) varies within the artery wall, even in health. The zones of hypoxia 
within atherosclerotic lesions (Figure 2b), may be formed because of impaired oxygen diffusion 
capacity as the atherosclerotic lesions enlarge, but may also be attributable to the high oxygen 
consumption of macrophage-derived foam cells.3  
Hypoxia has been consistently found in atherosclerotic plaques in vivo in humans and animal models 
including knock-out mouse models (apolipoprotein E; ApoE -/- and the low density lipoprotein 
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receptor; LDLr -/- mice).23 This has been demonstrated in vivo using various markers, including the 
chemical 7-(4'-(2-nitroimidazol-1-yl)-butyl) theophylline, that can be visualized using 
immunofluorescence.24 Other non-invasive imaging techniques have also been applied, that directly 
target plaque hypoxia, and these techniques are now being further validated in human studies. The 
metabolic marker F-fluorodeoxyglucose (FDG), has been used to detect human atherosclerosis in vivo 
18, and may also serve as an indirect marker of plaque hypoxia as the enhanced glucose uptake in 
anaerobic metabolism results in an increased uptake of the labelled FDG.25 Imaging plaque hypoxia 
could provide a means of assessing putative culprit lesions that are at risk of rupture, and are 
consequentially liable to adverse outcomes. Advanced aortic atherosclerosis was induced in cholesterol-
fed rabbits by balloon catheter injury, and F-18-fluoromisonidazole positron emission tomographic 
(PET) used for the in vivo assessment of hypoxia. This was then related to hypoxia assessed by ex-vivo 
tissue staining using pimonidazole, and immuno-staining for macrophages (RAM-11), new vessels 
(CD31), and hypoxia-inducible factor-1 α. Hypoxia was found to be predominantly confined to the 
macrophage-rich regions within the atheromatous core, whereas the macrophages close to the lumen 
were hypoxia negative. Intra-plaque new vessels were found predominantly in the macrophage-rich 
hypoxic regions (pimonidazole(+)/hypoxia inducible factor-1α(+)/RAM-11(+)).4 In human studies, this 
imaging approach has been coupled with quantitative polymerase-chain reaction (qPCR) and immune-
staining of plaques tissues recovered by carotid endarterectomy to determine the gene expression of 
HIF-1α and cluster of differentiation 68 (CD68, a marker of inflammation). HIF-1α and CD68 
expression were both found to be significantly correlated with F-FDG-uptake 18, indicating an 
association between the presence of hypoxia, inflammation and increased glucose metabolism in vivo.26  
Consequences of Hypoxia 
HIF is normally only found in hypoxic cells; in normoxia, it is degraded via the proteasome pathway. 
Prolyl 4-hydroxylases (PHDs), require oxygen for their catalytic activity, and function as cellular 
oxygen sensors, regulating the stability of HIF. In normoxia, 4-hydroxyproline residues are formed at 
specific sites on the HIF-1α subunit, catalyzed by PHDs, and this leads to its ubiquitination by the von 
Hippel Lindau E3 ubiquitin ligase and immediate destruction in proteasomes. This prevents the 
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formation of a functional HIF dimer (see Figure 1 27). Prolyl 4-hydroxylation is inhibited in hypoxia, 
facilitating the formation of the HIF dimer and the activation of its target genes, including those for 
erythropoietin (EPO) and vascular endothelial growth factor (VEGF). It has been proposed that the 
induction of a pseudo-hypoxia response by inhibiting HIF prolyl 4-hydroxylases may provide a novel 
therapeutic target in the treatment of hypoxia-associated diseases.28 Small-molecules, such as 
Roxadustat (FG-4592)29 and ZYAN130, have been developed to inhibit prolyl hydroxylase domain-
containing (PHD) enzymes, and cause HIF activation.31 These agents have been specifically applied to 
the treatment of renal anaemia.32 They can be administered orally are associated with an improved iron 
profile and an endogenous erythropoietin production near the physiological range. They are also likely 
to be cheaper to manufacture. The clinical trials currently underway will address whether PHD enzyme 
inhibitors will improve clinical end points, including cardiovascular events.33 PHD inhibitors have been 
reported to reduce blood pressure32 and plasma cholesterol concentrations.29 Hence there is good reason 
to believe that some PHD inhibitors will reduce cardiovascular endpoints in patients with renal disease. 
Whether they will benefit a broader category of patients with high risk of cardiovascular disease is 
difficult to predict. 
The HIF-α subunits are also involved in other key pathways for the adaptation to hypoxia, including 
VEGF 34 and nitric oxide synthase (NOS) (Heikal et al 2016 in press). 
The hypoxia/ reoxygenation cycle leads to the formation of reactive oxygen species (ROS) that may 
subsequently regulate HIF-1 but in a rather complex manner. It has been suggested that ROS promote 
angiogenesis, either directly via stimulation of HIF-1 genes that are involved in stimulating 
angiogenesis, such as NOS and NADPH oxidase or via the generation of active oxidation products, 
including lipid peroxides. ROS are associated with the development of several chronic diseases that 
include atherosclerosis, type 2 diabetes mellitus, and cancer (reviewed in Gorlach et al 2015 35). HIF-
1α plays a key role in the progression of atherosclerosis by initiating and promoting the formation of 
foam cells, endothelial cell dysfunction, apoptosis, increasing inflammation and angiogenesis.36 
Although ROS have damaging effects on tissues, causing cell death, at high concentrations, lesser 
degrees of oxidative stress may play a positive role during angiogenesis, or other pathophysiological 
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processes. Angiogenesis induced by oxidative stress involves vascular endothelial growth factor 
(VEGF) signalling, although VEGF-independent pathways have also been identified.37 
It has been proposed that the state of hypoxia, present in the atherosclerotic plaques of mice deficient 
in apolipoprotein E (ApoE-/- mice), may promote lipid synthesis, and reduce cholesterol efflux through 
the ABCA1 pathway; processes that are known to be mediated by HIF-1α.23 Hypoxia has also been 
reported to increase the formation of lipid droplets in macrophages to promote the secretion of 
inflammatory mediators, and atherosclerotic lesion progression by exacerbating ATP depletion and 
lactate accumulation in this model of atherosclerosis.38 
Systemic hypoxia that is, for example associated with obstructive sleep apnoea (OSA) also promotes 
atherosclerosis. The processes by which it may do this include effects on lipid metabolism and efflux, 
inflammation, altered macrophage polarization and glucose metabolism.39 The effect of hypoxia on 
other mediators will be discussed further below. 
Models used to assess the effects of mediators on HIF-1 expression  
1. In vitro models 
Endothelial and Endothelial Progenitor cells 
Endothelial dysfunction is one of the first manifestations of atherosclerosis.40 It is associated with a 
deficiency of biologically active nitric oxide (NO).41 After chronic inhibition of endothelial nitric oxide 
synthase (eNOS), either pharmacologically using NG-Nitro-L-arginine methyl ester (L-NAME) or using 
RNA interference, HUVECs were found to have a higher migratory capability, which was accompanied 
by an increased expression of VEGF and the VEGF receptor-2 (kinase insert domain receptor, KDR). 
Inhibition of eNOS, induced a state of pseudohypoxia (a state under which cells activate a hypoxic 
response in the presence of oxygen), evidenced by stabilization of HIF-1α. Furthermore, reduced NO 
expression was associated with significant mitochondrial dysfunction with a consequential decrease in 
energy production and oxygen consumption. The basal release of NO may act as a negative regulator 
of HIF-1α levels, and this may have important consequences for endothelial cell physiology.42 The 
reported effects of NO on HIF-1 expression have been inconsistent.43, 44 Nitrate and nitrite can be 
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metabolized in vivo to form NO and other bioactive nitrogen oxides, providing an important alternative 
source of NO during hypoxia when the oxygen-dependent L-arginine-NO pathway may be altered (see 
Figure 3).45 
Nuclear factor-kappa B (NF-kappa B); is a redox-sensitive transcriptional factor. NF-kappa B and HIF-
1 are both implicated in the expression of pro-inflammatory cytokines during intermittent hypoxia/ 
reperfusion (IHR). IHR is a feature of obstructive sleep apnoea (OSA) and an independent risk factor 
for the development of coronary and cerebral vascular diseases. In vitro studies using EA.hy926 cells 
(a human vascular endothelial cell line), showed that IHR induced the activation of NF-kappa B and 
HIF-1, enhanced the mRNA expression of pro-inflammatory cytokines and increased the activation of 
p38 MAPK which is critical for the production of NF-kappa B. Propofol (2,6‑di-isopropylphenol), is a 
potent intravenous anaesthetic agent that attenuates the IHR-induced activation of NF-kappa B dose-
dependently. This effect was accompanied by decreased levels of pro-inflammatory cytokines without 
changing the activation of HIF-1. This effect is likely to be mediated via the inhibition of the p38 MAPK 
signalling pathway. Hence Propofol may have the potential to prevent atherosclerosis in patients with 
OSA by inhibiting NF-kappa B mediated inflammation in the vascular endothelium.46 
Endothelin-1 (ET-1) is a potent vasoconstrictor that is predominantly expressed in vascular endothelial 
cells, as well as by other cells and tissues. Increased plasma levels of ET-1 are associated with 
atherosclerosis. Hypoxia is one of the most potent inducers of ET-1 gene expression in endothelial cells 
and may be the primary cause of the increased production of ET-1 during myocardial ischemia. Hypoxia 
induces the synthesis and secretion of ET-1 in isolated endothelial cells by a mechanism that is 
antagonized by NO and carbon monoxide and mimicked by transition metals. The induction of ET-1 
by hypoxia in vitro has been reported to occur exclusively in early passage endothelial cells where it 
requires endothelial cell specific factors, new protein synthesis (synthesis inhibited by a protein 
synthesis inhibitor; cycloheximide) and may involve a non-heme oxygen binding enzymes.47 
Intercellular adhesion molecule-1 (ICAM-1) is a cell surface glycoprotein typically expressed on 
endothelial cells, but found as a soluble form (sICAM-1) in plasma. It is thought to be a key molecule 
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involved for the attachment of circulating monocytes to the endothelium and their subsequent 
transmigration into the intima. Its levels in plasma are related to the severity of atherosclerosis and can 
predict future cardiovascular events.  Increased expression of endothelial ICAM-1 is also related to the 
chronic effects of oxidative stress. Ziegelstein et al. found that when human aortic endothelial cells 
(HAECs) were exposed to hypoxia/ re-oxygenation (H/R), hypoxia alone was insufficient to increase 
either ROS production or ICAM-1 mRNA levels, but a 2.5-fold increase in ICAM-1 mRNA was noted 
after 30 min of re-oxygenation. This was not observed in a Ca2+ free buffer or in cells treated with a 
ROS inhibitor; diphenyleneiodonium. Thus, H/R upregulates ICAM-1 mRNA in HAEC via a Ca2+ and 
ROS-dependent mechanism. The characterization of the signalling pathways involved in H/R-induced 
adhesion molecule expression may result in a better understanding of the pathobiology of 
atherosclerosis and of the vascular biology of normal aging.48, 49 
AMPK (AMP-activated protein kinase) is a key enzyme in the regulation of cellular energy and has 
cardiovascular protective effects.50 It can detect changes in AMP levels, but may also be activated in 
endothelial cells by an AMP-independent mechanism, involving mitochondrial ROS, generated as a 
result of the interaction between NO and mitochondrial cytochrome c oxidase at low oxygen 
concentrations. In hypoxia, a reduction in ATP, and the breakdown of ADP to AMP could also activate 
AMPK.51 AMPKα1 is responsible for the expression of genes involved in antioxidant defence, 
including: manganese superoxide dismutase (MnSOD), catalase, gamma-glutamylcysteine synthase 
and thioredoxin. Silencing of AMPKα1 has been reported to reduced mitochondrial and eNOS content, 
reduced cell proliferation, increased accumulation of ROS and apoptosis. Thus in HUVECs, AMPKα1 
regulates both their mitochondrial content and their antioxidant defences, and is therefore likely to be 
beneficial in those conditions mediated by oxidative stress, and where dysfunction of AMPK may 
contribute to the initiation and progression of atherosclerosis.52, 53 
Vascular endothelial cells synthesize heparan sulphates. Heparan sulphates expressed on the surface of 
endothelial cells, contribute to their antithrombotic properties by facilitating thrombin inactivation by 
anti-thrombin III; this is mediated by the heparin-like sequences within the heparan sulphate chains to 
which both anti-thrombin and thrombin may bind. Macrophages are proposed to be a major source of 
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heparan sulphate in atherosclerotic lesion, and this may be modulated by oxygen tension.54 Furthermore, 
Karlinsky et al. showed that when bovine aortic and pulmonary endothelial cells were cultured under 
hypoxic conditions (3% oxygen), cell layer-associated heparan sulphate was reduced substantially 
(>45%). The degradation of heparan sulphate was not affected by hypoxia, however, the percentage of 
the heparan sulphate that bound to antithrombin III was increased significantly (>33%). The total 
quantity of heparan sulphates synthesized by the cultured endothelial cells was also affected during 
exposure to 3% oxygen, but not to the same extent; the authors therefore concluded that hypoxia may 
differentially influence the chain length and anti-thrombin III-binding capacity of heparan sulphate 
species. This would be important in helping to maintain a non-thrombogenic surface under hypoxic 
conditions and the hypoxia-induced modification of heparin sulphate may therefore be of relevance to 
the development of atherosclerotic lesions.55 
Endothelial progenitor cells EPCs, contribute to vascular repair. They are released into the circulation 
from the bone marrow, and can adhere to the endothelium at sites of injury and hypoxia.56 They can 
also contribute to the formation of new vessels following their differentiating into endothelial cells 
(ECs). Apelin is an endogenous ligand for the G protein-coupled receptor APJ, and apelin/ APJ 
signalling appears to be involved in a wide range of physiological and pathological functions in the 
cardiovascular system. It is also involved in the regulation of EPC proliferation in hypoxic conditions.57 
HIF-1α promotes the expression of apelin and APJ, which then activate the downstream PI3K/ Akt 
signalling pathway, a key promoter of EPC proliferation. Apelin is therefore proposed to be a novel 
factor in the development of atherosclerosis.57, 58 
EPO is a 30,400-dalton glycoprotein that regulates red blood cell production. It circulates in plasma and 
controls the oxygen carrying capacity of the blood.59 EPO is produced primarily in the adult kidney and 
foetal liver. However it is now well established that several cell types express EPO or its receptor 
(EPOR),60 including vascular smooth muscle 61 and endothelial cells.62 In these cells EPO exerts a 
number of effects including protection against apoptosis, 63 mitogenic and chemotactic effects 
(reviewed by Ribatti et al. 64). It also stimulates a significant increase in circulating endothelial 
progenitor cells. EPO plays an important role in regulating angiogenesis.65 Whilst EPO enhances 
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endothelial repair in models of vascular injury, its reported effects on neo-intima formation in animal 
models has been inconsistent, with some investigators reporting enhanced neo-intima formation despite 
complete re-endothelialization,66 and others reporting an inhibition of neo-intima formation that was 
NO-dependent.67 In human studies EPO treatment was associated with an increase in neo-intima 
generation in patients treated with percutaneous coronary intervention.68 Furthermore, EPO retards the 
progression of atherosclerosis. EPO and one of its non-erythropoeitic analogues (HBSP; 30 µg/Kg body 
weight) reduces the cholesterol ester content of aortic tissue in the Watanabe heritable hyperlipidemic 
(WHHL) rabbits and the intima-media thickness in renal patients undergoing haemodialysis. EPO (5 
U/mL) has been shown to suppress foam cell formation in murine macrophages by promoting the 
efficacy of cholesterol efflux.69-71 EPO also has protective effects against stress that are related to energy 
metabolism where it is involved in the regulation of metabolic cell activity, cellular respiration and 
mitochondrial function via important energy regulation factors such as AMPK.72 
Tissue hypoxia is the main stimulus of EPO production. Oxygen-dependent regulation of EPO gene 
expression is controlled primarily by the transcription factor HIF-2α rather than HIF-1α.73The response 
of vascular endothelial cells to EPO is enhanced at a low oxygen concentrations (5% or 2%); this has 
in particular been shown for its effect on NO release. EPOR is inducible by EPO (5 U/mL) in primary 
human umbilical vein endothelial cells (HUVECs) and artery (HUAECs) and cells derived from a 
human bone marrow microvascular endothelial line (TrHBMEC).  
Hypoxia can also induce the mobilization of EPCs via a NADPH oxidase (Nox2) dependent pathway. 
Nox2 is an important source of ROS. This response is abolished in Nox2 knockout mice Nox2(y/-). 
EPO is also known to induce EPC mobilization and this too appears to be Nox2 dependent. ROS are 
the product of the enzymatic reaction catalysed by Nox2, and EPO was found to increase ROS 
production, and the migration and proliferation of EPCs derived from WT mice, but no increase of ROS 
formation was observed in Nox2-deficient EPCs. Furthermore, re-endothelialisation of the injured 
mouse carotid artery was enhanced by hypoxia, or EPO, and this effect was not observed in Nox2(y/-) 
mice or after transplantation of Nox2(y/-) bone marrow cells. Over-expression of the EPO receptor can 
increase EPO-dependent signalling. Ligand-induced EPO receptor dimerization, allows binding of 
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JAK2. JAK2 then creates SH2 binding sites by phosphorylating tyrosine residues on the EPO receptor. 
Phosphorylation of the receptor activates Rac1 and PI3K which in turn leads to the assembly of Nox2-
containing NADPH oxidase that subsequently synthesize superoxide anions. STAT5 also binds to the 
SH2 domains of the EPO-receptor, where it is phosphorylated, dimerizes, and eventually translocates 
to the nucleus. It then initiates the transcription of several target genes and leads to cell proliferation, 
migration, and mobilization. In the absence of ROS production by Nox2, STAT5 is dephosphorylated 
before STAT5- mediated signalling can occur. siRNA against the redox-sensitive phosphatase SHP-2 
restored EPO-mediated STAT5 induction and inhibition of SHP-2 restored EPO-induced migration in 
Nox2-deficient cells. It therefore appears that Nox2-derived ROS inactivate SHP-2 and thereby 
facilitate EPO signalling in EPCs to promote hypoxia-induced mobilization and vascular repair by these 
cells.74 
Endothelial cells release ATP in response to changes in blood flow (producing shear stress), or hypoxia, 
where it acts on ATP receptors (P2X and P2Y) on the endothelial cells to produce NO, PGI2 and 
endothelium-derived hyperpolarizing factor (EDHF), which contribute to blood vessel dilatation. ATP 
is also released from sensory-motor nerves during anti-dromic reflex activity to produce relaxation of 
some blood vessels. The purine and pyrimidine nucleosides and nucleotides have long-term (trophic) 
actions in promoting migration and proliferation of both vascular smooth muscle and endothelial cells 
via adenosine receptor (P1) and ATP receptors (P2Y) during angiogenesis and vessel remodelling 
during restenosis after angioplasty.75, 76 
Endothelial cells express receptors for very low density lipoprotein (VLDLr). In addition to their 
function as peripheral lipoprotein receptors, VLDLrs have other possible biological roles including in 
signal transduction, angiogenesis, and tumour growth. Some recent studies suggest that the VLDLr has 
a regulatory role in endothelial pathology. The activation of retinal vascular endothelial cells and 
promotion of angiogenesis are mediated through the VLDLr. Hypoxia can trigger endothelial 
endoplasmic reticulum (ER) stress and apoptosis, and induce the expression of VLDLr through the 
interaction of HIF-1α with the hypoxia responsive element (HRE) at the VLDLr promoter. VLDLr then 
mediates the ER stress response and apoptosis.77  
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High density lipoproteins (HDLs) are thought to be involved to reverse cholesterol transport 
(transporting cholesterol from peripheral tissue back to the liver), and have therefore been proposed to 
have a protective role in atherosclerosis.78 HDLs also appear to promote hypoxia-induced 
angiogenesis.79 In hypoxia, recombinant HDL (rHDL) augments the HIF-1/VEGF pathway via 
scavenger receptor class B type 1 (SR-BI), leading to the modulation of the post-translational regulators 
of HIF-1 (PI3K/ Siahs/PHDs); crucial mediators in angiogenesis. Despite strong epidemiological and 
pre-clinical evidence for the athero-protective effects of HDL, recent HDL-raising clinical trials have 
been unable to show cardiovascular benefits.79 Augmentation of angiogenesis and the HIF-1/VEGF 
pathway in hypoxia may have important implications for the targeting of HDL-raising therapies, 
particularly for the prevention of ischemic injury after myocardial infarction.80 
CD40 and its ligand (CD40L) have been implicated in the pathogenesis of atherosclerosis; the 
interaction between CD40 and CD40L is involved in the activation of antigen presenting cells, such as 
macrophages. This interaction modulates the generation of endothelial ROS. It has been found that 
hypoxia enhances the inflammatory effect of CD40L in both endothelial and monocytic cells (THP1) 
and induces ROS production, the synthesis of ICAM1 and activates stress response proteins (p38 MAP 
kinase and HSP27), indicating that CD40L mediates the induction of oxidative stress in these cells. The 
interaction between CD40–CD40L is augmented in hypoxia playing a potentially important role in 
vascular inflammation, cellular adhesion and angiogenesis; processes involved in atherosclerosis.81 
The retinoic acid-related orphan receptor α (RORα) is involved in regulating inflammatory and immune 
responses and lipid metabolism. RORα mRNA has been detected in endothelial cells and smooth muscle 
cells. Its expression is significantly decreased in atherosclerotic plaques. Plasma and intracellular levels 
of cholesterol may be important in the regulation of the transcriptional activity for RORα. Hypoxic 
conditions induce the expression of RORα and when cells were treated with RORα, the transcriptional 
activity of HIF-1α was enhanced. RORα was reported to be physically associated with HIF-1α via its 
DNA binding domain, and this was required for the RORα-induced stabilization and transcriptional 
activation of HIF-1α. In vitro, ROR ligands enhance the formation of capillary tubes by human 
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umbilical vascular endothelial cells suggesting a potential involvement of ROR and its ligands in the 
major clinical endpoints associated with atherosclerosis.82, 83 
Atherosclerosis is associated with decreased endothelial NO production. NO normally reduces cellular 
oxygen consumption by competitively inhibiting cytochrome c oxidase. Endothelial NO, can therefore 
modulate O2 consumption in conductance vessels and the microcirculation, and appears to regulate O2 
distribution to the surrounding tissues. Removal of NO abolishes this regulatory function. Hence 
endothelial NO plays a major role in facilitating the distribution of O2, which is crucial for the adaptation 
of tissues, including the vessel wall itself, to hypoxia.84-86  
Vascular smooth muscle cells 
Smooth muscle cell proliferation is increased in pathological conditions, including atherosclerosis, 
resulting in the thickening of the vessel walls.87 The migration of vascular smooth muscle cells 
(VSMCs) from the tunica media to the intima and their proliferation under the influence of growth 
factors such as platelet-derived growth factor is a critical step in atherogenesis.88 The proliferation and 
migration of vascular smooth muscle cells is also involved in new vessel formation (angiogenesis) and 
this is co-ordinated by a number of factors that include VEGF.89 
VEGF is a hypoxia-inducible angiogenic factor. It also mediates the angiogenic effects of other growth 
factors that are not themselves direct endothelial cell mitogens. Exposure of VSMCs to a threshold 
hypoxic stimulus (2.5% O2,) causes a modest increase in VEGF mRNA levels. These effects of hypoxia 
are synergistic with basic fibroblast growth factor (bFGF) which also plays a role in inducing 
angiogenesis. This synergistic effect on VEGF expression appears to be specific as hypoxia has not 
been found to enhance the bFGF-induced expression of the proto-oncogene c-myc (the gene responsible 
for cell proliferation). bFGF may therefore promote angiogenesis both by a direct effect on endothelial 
cells and indirectly by the up-regulation of VEGF in VSMCs. The synergy demonstrated between 
hypoxia and bFGF suggests that multiple diverse stimuli may interact via the up-regulation of VEGF 
expression in VSMCs to amplify the angiogenic response.90 The increased expression of VEGF 
following exposure to hypoxia is also enhanced by platelet-derived growth factor-BB (PDGF-BB). The 
 
16 
Ferns and Heikal, Atherogenesis and hypoxia 
 
synergy between hypoxia and PDGF-BB was again found to be selective for VEGF expression as 
hypoxia had no effect on the PDGF-induced upregulation of the proto-oncogene c-myc.91  
Moderate hypoxia (5% O2) has also been reported to enhance the proliferative responses of human 
pulmonary artery SMC (HPASMC) to mitogens including PDGF, bFGF, and epidermal growth factor 
(EGF). Moderate hypoxia also elicited increased cellular HIF-1α levels, and enhanced PDGF-, bFGF, 
and EGF-induced expression of HIF-1α. These effects were abrogated by the knocking-down of HIF-
1α using specific small interfering RNAs but this failed to inhibit the co-mitogenic effect of hypoxia. 
Hence HIF-1α promotes proliferative responses of human VSMC to bFGF, PDGF, and EGF by 
mechanisms that may involve HIF-1 dependent expression of cyclin A, but HIF is apparently not crucial 
to the enhancement of bFGF, PDGF, and EGF-induced proliferation of VSMC that occurs during 
hypoxia.92 
Hypoxia increases cytosolic calcium concentration, enhances prostaglandin (PG) release and synthesis 
of platelet-activating factor (PAF) in endothelial cells and increases neutrophil adherence. Hypoxia may 
also change the balance between endothelial cell-derived growth inhibitors and activators for SMCs, 
shifting it to a more pro-proliferative activity which could explain the proliferation of SMCs observed 
in vivo in some pathological conditions, such as atherosclerosis. Michiels et al. investigated the 
influence of hypoxic endothelial cell-conditioned media on SMC proliferation. HUVECs exposed to 
hypoxia, elaborate mitogenic factors that had a pro-proliferative effect on SMC that was not inhibited 
if the HUVECs were treated with the protein synthesis inhibitor, cycloheximide, but was blocked if 
prostaglandins (PGs) synthesis was inhibited during hypoxia. Therefore it appears that PGs and bFGF 
are responsible for this pro-proliferative activity and their effect is additive.87 
Proteoglycan are important constituents of the arterial wall extracellular matrix, and participate in 
normal vascular homeostasis and function, as well as in the trapping and modification of serum-derived 
lipoproteins. The majority of proteoglycans in the artery wall are produced by vascular endothelial cells 
and SMCs. The proteoglycans secreted by smooth muscle cell cultures exposed to hypoxia/ re-
oxygenation are increased substantially compared to cells exposed to continuous normoxia. The newly 
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synthesized proteoglycans synthesized by SMCs exposed to either condition did not differ in their 
charge densities or molecular weight but did differ in glycosaminoglycan (GAG) composition. In the 
cells exposed to hypoxia /reoxygenation there was a 60% increase in a proteoglycan sub-fraction that 
bound LDL with very high affinity. Hypoxia followed by re-oxygenation is perhaps a more important 
signal for smooth muscle cell changes, including induction of synthesis of a proteoglycan species with 
very high affinity binding for plasma LDL.93 
Human coronary artery smooth muscle cells (CASMCs) cultured under hypoxic conditions (1% O2, 
5% CO2) have been found to express increased levels of VEGF, VEGF receptor-1 (VEGFR-1) and 
HIF-1α. Hypoxia was associated with enhanced [H3]-thymidine incorporation, which was completely 
inhibited by a neutralizing antibody against VEGF and attenuated by a neutralizing antibody against 
NADPH-cytochrome P-450 reductase (NPR), which contributes to the stabilization of HIF-1α. The 
effects of hypoxia were also attenuated in NPR-knock down cells, and enhanced in NPR-over-
expressing cells. Hypoxia-induced proliferation of CASMCs is mediated by an increased expression of 
VEGF and VEGFR-1, acting via an autocrine mechanism. The expression of these two molecules is 
dependent on the stabilization of HIF-1α, which is regulated by NPR. It has therefore been suggested, 
that hypoxia as well as NPR are implicated in the pathogenesis of progressive atherosclerosis.94 
Thrombospondin-1 (TSP-1) is also associated with the formation of atherosclerotic lesions, acute 
vascular injury, hypercholesterolemia, and hypertension. The administration of antibodies against TSP-
1 has been shown to significantly accelerate re-endothelialization and reduce neo-intima formation in 
balloon-injured rat arteries. TSP-1 has been reported to be a potent inducer of the migration of bovine 
pulmonary artery smooth muscle cells and human vascular smooth muscle cells (VSMCs). When 
human coronary artery smooth muscle cells (CASMCs) were cultured under hypoxic conditions, 
mRNA and protein levels of thrombospondin-1 (TSP-1), and mRNA levels of integrin β(3) were 
increased with the increase in HIF-1α protein. DNA synthesis and migration of the cells were stimulated 
under these conditions, and a neutralizing anti-TSP-1 antibody apparently suppressed the migration, but 
not DNA synthesis. The migration was also inhibited by the tripeptide Arg-Gly-Asp (RGD) that binds 
to integrin β(3). Furthermore, the migration was completely suppressed in HIF-1α-knockdown cells 
 
18 
Ferns and Heikal, Atherogenesis and hypoxia 
 
exposed to hypoxia and enhanced in HIF-1α-overexpressing cells. These results suggest that hypoxia 
enhances the migration of CASMCs, and that the migration is elicited by TSP-1, the induction of which 
is dependent on the stabilization of HIF-1α.95 
Macrophage migration inhibitory factor (MIF) has emerged as a key factor in vascular re-modelling 
and in the development and progression of atherosclerosis. MIF is an essential, upstream component of 
the inflammatory cascade and has a critical role in several inflammatory conditions. It can be expressed 
by vascular endothelial cells, VSMCs and macrophages. Increased expression of vascular MIF is 
associated with foam cell transformation during atherogenesis. MIF is expressed in atherosclerotic 
lesions, and it has been suggested to be involved in atherosclerotic plaque development. Several pro-
atherosclerotic mediators such as oxidized LDL, CD40-L and angiotensin II are able to stimulate MIF 
expression. MIF mRNA and protein were found to be up-regulated early after exposure to moderate 
hypoxia (3% O2) in cultured human VSMCs. This is HIF-1α dependent, since knockdown of HIF-1α 
was found to inhibit the hypoxia induced induction of MIF gene and protein expression. This up-
regulation of MIF was attenuated by antioxidant treatment and by inhibition of extracellular signal-
regulated kinase (ERK). Under moderate hypoxia (3% O2), both cell proliferation and cell migration 
were increased in VSMC cells. Blocking the MIF by specific small interference RNA to MIF (MIF-
shRNA) resulted in the suppression of proliferation and migration of VSMCs.96 
Leptin is a adipose tissue derived hormone involved in weight regulation.97 Leptin has now been 
reported to be hypoxia-inducible 98 and may be involved in the pathogenesis of atherosclerosis by 
initiating leukocyte and macrophage recruitment to the endothelium.99 Leptin also has several other pro-
atherogenic properties; it stimulates the proliferation of VSMCs and their production of 
metalloproteinase. In addition, leptin promotes the production of proliferative and inflammatory 
cytokines, it increases platelet aggregation and enhances the secretion of pro-atherogenic lipoprotein 
lipase by cultured human and rodent macrophages causing endothelial dysfunction through the 
induction of AngII, ROS, and the JNK pathway.100 
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An adverse intrauterine environment during a critical period in foetal development may increase 
subsequent risk of cardiovascular disease in adulthood.101 Chronic hypoxia during gestation is 
considered to be one of the most common intrauterine stressors and Lv et al. showed that exposure of 
neonatal rat aorta smooth muscle cells (NRSMCs) to 2% oxygen enhanced their proliferation in a time-
dependent manner, and decreased their rate of apoptosis. This was associated with reduced levels of 
levels of the pro-apoptotic proteins, BNIP3 and bax, and an increase in the anti-apoptotic factor bcl-2 
under hypoxic conditions. Specific down-regulation of HIF-1α partly abolished the proliferative effect 
of hypoxia.102 
Dipeptidyl peptidase 4 (DPP4) is a 110 kDa glycoprotein, expressed on several cell types and the 
expression of which is upregulated following exposure to moderate hypoxia (3% O2) Matrix 
metalloproteinase (MMP)-1, -2 and 14 are involved in the shedding of DPP4 from human vascular 
smooth muscle cells both constitutively as well as under hypoxic conditions. It has been reported that 
increased DPP4 shedding from SMC occurs due to a complex interplay between different MMPs in cell 
type-specific manner 103, 104, and that DPP-4 inhibitors, such as alogliptin have anti-atherosclerotic 
properties.105 
Obstructive sleep apnoea (OSA) is characterized by intermittent hypoxia (IH), and is associated with 
an increased risk of cardiovascular disease. IH induces VSMC proliferation, possibly mediated in part 
by members of the epidermal growth factor family (EGF), such as epiregulin (ER), amphiregulin (AR) 
and neuregulin-1 (NRG1), and the EGF receptor (erbB2) may be involved in the IH-induced VSMC 
proliferation.106 IH induces the expression of HIF-1 dependant genes, including VEGF and NF-Kappa 
B as well as the release of reactive oxygen species.107 However, there is still debate as to whether HIF-
1α is activated during OSA and IH. 
Low-density lipoprotein receptor-related protein (LRP1, also termed the apoE receptor) plays an 
important role in lipoprotein metabolism and vascular function. In VSMCs exposed to hypoxia (1% O2) 
there was a time-dependent induction of LRP1 mRNA and protein expression, with maximum levels 
being observed at 12 to 24 hours following exposure. This effect was mediated by HIF-1α and was 
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found to result in increased cholesteryl ester (CE) accumulation due to an increased uptake of modified 
(aggregated) low-density lipoprotein (agLDL). Blockade of HIF-1α expression inhibited the up-
regulatory effect of hypoxia on LRP1 expression and agLDL-derived intracellular CE accumulation, 
suggesting that both LRP1 overexpression and increased CE accumulation in hypoxic VSMCs are 
dependent on HIF-1α.108 
Resistin is a cysteine-rich adipose-derived peptide hormone that in humans is encoded by the RETN 
gene.109 It produces pro-inflammatory effects in the vascular wall.110, 111 It promotes endothelial cell 
activation and causes endothelial dysfunction of porcine coronary arteries. Resistin was reported to have 
a potential pro-atherogenic effect by increasing the expression of pro-inflammatory cytokines in 
vascular endothelial cells, and through its promotion of VSMC proliferation. Hypoxia significantly 
increases the expression of resistin protein and mRNA in rat aortic SMCs. The specific extracellular 
signal-regulated kinase (ERK) inhibitor PD98059, antioxidant N-acetylcysteine, and ERK siRNA all 
attenuated the induction of resistin protein by hypoxia. Resistin also increases reactive oxygen species 
production that could be blocked by pre-treatment with N-acetylcysteine. Hence it appears that the 
hypoxia-induced increase in resistin is mediated through ROS, ERK mitogen-activated protein (MAP) 
kinase and nuclear factor of activating T cells pathway.112 
Monocyte/ macrophage 
Angiogenesis is increased in lipid-rich plaque. Oxidized low-density lipoprotein (ox-LDL) is generated 
in lipid-rich plaque by oxidative stress. It triggers an inflammatory response to cause endothelial 
dysfunction. However, ox-LDL can activate HIF-1α in monocytes in a hypoxia-independent manner. It 
has been hypothesized that HIF-1α activation in monocyte-macrophages could transmit pro-angiogenic 
effects of ox-LDL linking hyperlipidemia, inflammation, and angiogenesis in atherosclerosis. Ox-LDL 
has been reported to strongly induce HIF-1α and VEGF in monocyte-macrophages and increase 
endothelial tube formation in co-cultured endothelial cells. HIF-1α inhibition reversed this effect. There 
was a direct pro-angiogenic effect of ox-LDL in an in vivo angiogenesis assay. Again, HIF-1α inhibition 
abrogated the pro-angiogenic effect of ox-LDL. In a rabbit model, administration of a low-lipid diet 
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significantly reduced the expression of both HIF-1α and VEGF, resulting in decreased plaque neo-
vascularization.113  Ox-LDL appears to be a pro-angiogenic agent linking hyperlipidaemia, 
inflammation, and angiogenesis in atherosclerosis. Hence this effect is dependent on macrophages and 
on the induction of the HIF-1α pathway converting monocyte–macrophages into potent pro-angiogenic 
cells. This mechanism could underlie the previously reported property of ox-LDL as a marker of 
atherosclerosis progression in patients with coronary artery disease.113 
Monocytes migrate from the circulating blood where the oxygen tension is high, to the arterial wall 
where the oxygen tension is low. This change in the micro-environmental oxygen concentration may 
affect the metabolism of LDL by the monocyte-derived macrophage. Whilst the specific binding and 
association of LDL are not changed by hypoxia, the degradation of LDL is reduced to 60% of its rate 
in normoxia, and the rates of cholesterol esterification and cellular accumulation are increased. The 
secretion of ApoE is not altered under hypoxia, and therefore it is likely that ApoE-independent 
cholesterol efflux is reduced. Therefore, hypoxia affects the intracellular metabolism of LDL, stimulates 
cholesterol esterification, and enhances cholesteryl ester accumulation in macrophages.114 
Transmigration of monocyte-derived macrophages into the sub-endothelial space is also a crucial step 
in atherogenesis. Pro-inflammatory macrophages ingest ox-LDL via scavenger receptors and become 
foam cells, thereby promoting plaque formation. Foam cell formation is a key event in both early and 
late atherosclerotic lesions.18 Although a number of proteins may contribute to this process, scavenger 
receptors A (SRA), lectin-like ox-LDL receptor (Lox-1), and cluster of differentiation 36 (CD36) have 
been demonstrated to be the most relevant for cholesterol uptake.115 mRNA and protein expression of 
SRA and CD36 are upregulated by ox-LDL, but are decreased following exposure of macrophages to 
hypoxia.116 In contrast, Lox-1 mRNA and protein levels were shown to be upregulated under hypoxic 
conditions.116 In this study it was also shown that there was an increase in the lipid content of 
macrophages after exposure to 0.2% oxygen or treatment with the hypoxia-mimetic 
dimethyloxalylglycine (DMOG). Blocking of the Lox-1 receptor decreased the hypoxic induction of 
ox-LDL uptake and lipid content of macrophages. RNAi-mediated knock-down of HIF-1α in 
macrophages was found to attenuate the hypoxic induction of Lox-1. Hence hypoxia increases the lipid 
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uptake by macrophages and differentially regulates the expression of ox-LDL receptors. Lox-1 plays a 
major role in hypoxia-induced foam cell formation which is, at least in part, mediated by HIF-1α. It has 
been proposed that HIF-1α is involved in Lox-1 upregulation, thereby enhancing ox-LDL uptake. 116. 
Furthermore, Burke et al showed that RNA interference for HIF-1α (HIF-1α-siRNA) inhibited foam 
cell formation in the human monoblastic cell line (U937) treated with ox-LDL while several 
atherosclerosis-related genes, such as cyclooxygenase-2 (COX-2), vascular cell adhesion molecule-1 
(VCAM-1) and interleukin-1 β (IL-1 β) were down regulated. Hence the induction of HIF-1α by 
atherogenic factors may be involved in coordinating the cellular events that culminate in the formation 
of atherosclerotic lesions.117 
ATP-binding cassette transporter A1 (ABCA1) plays an important role in reverse cholesterol transport 
(RCT), a process that is involved in atherogenesis. During atherogenesis, lipid loaded macrophages are 
exposed to regions of local hypoxia that may influence RCT and affect the lipid efflux of macrophages 
in the arterial wall. HIF-1 binds to the HRE region of the ABCA1 promoter and the HIF-1 complex 
increases ABCA1 promoter activity and ABCA1 expression. Primary human macrophages exposed to 
hypoxia or constitutively expressing active HIF-1α have been found to respond with a potent change in 
ABCA1 expression, which shows a strong correlation with HIF-1β expression. Furthermore, ABCA1-
mediated cholesterol efflux was found to be regulated by HIF-1β under hypoxia. In vivo, in 
macrophages prepared from human atherosclerotic lesions, HIF-1β acted as a major regulator of 
ABCA1 expression under hypoxia. HIF-1β availability could therefore determine ABCA1 expression 
and cholesterol efflux in macrophages under hypoxia.118 
The AMP-activated protein kinase (AMPK) was initially identified as the kinase that phosphorylates 3-
hydroxy 3-methylglutaryl coenzyme A reductase (HMGCoA reductase, the rate-limiting enzyme for 
cholesterol biosynthesis). AMPK is activated by increased concentration of AMP. Hypoxia stimulates 
AMPK in activated monocytes. Stimulation of macrophages with the anti-inflammatory cytokines 
interleukin-10 and transforming growth factor-β (TGFβ) resulted in the rapid phosphorylation of 
AMPK, whereas stimulation of macrophages with lipopolysaccharide resulted in AMPK 
dephosphorylation and inactivation. AMPK directs signalling in macrophages in a way that suppresses 
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pro-inflammatory responses and promotes macrophage polarization to an anti-inflammatory functional 
(M2) phenotype.119 
Several mechanisms are involved in controlling monocyte and macrophage motility in response to 
hypoxia. Chemokinesis (the motility of cells) is enhanced in human monocyte derived macrophages 
(HMDM) after 24 h exposure to low O2 tension (0.5%) compared to cells grown under normoxia. Cell 
surface heparan sulphate proteoglycan (HSPG) bind cytokines, chemokines, and growth factors and 
regulate a wide variety of biological activities, including cell migration, cell adhesion, proliferation, 
receptor interaction, coagulation, and lipoprotein binding and uptake. Macrophages appear to play a 
role in the synthesis of cell membrane HSPG associated with CVD. There are two types of cell 
membrane HSPG; the transmembrane syndecans and the GPI-anchored-glypicans. HMDM exposed to 
hypoxia for 24 hours had a lower mRNA expression of syndecan-1 and -4 compared with cells exposed 
to normal cell culture conditions. Protein levels of syndecan-1 were also decreased significantly and 
cells exposed to hypoxia had lower mRNA expression for key enzymes involved in HS biosynthesis.54 
A critical step in the development of atherosclerotic plaques appears to be the retention of apoB-100-
containing lipoproteins in the arterial wall, and this is partially mediated by the interaction between 
positively charged regions of apoB-100 and the negatively charged glycosaminoglycan (GAG) chains 
of proteoglycans (PG) in the intima. Macrophages secrete PG, such as versican, that can alter the 
retention of lipoproteins and the activity of enzymes, cytokines, and growth factors involved in 
atherogenesis. They can secrete other PG including perlecan and serglycin, and macrophage colony 
stimulating factor (MCSF). Versican has been found to be co-localized with HIF-1α in macrophage-
rich areas in human advanced atherosclerotic lesions. In vitro, versican and perlecan mRNA expression 
increased after exposure to hypoxia. Furthermore, siRNA knockdown of HIF-1α and HIF-2α in the 
THP-1 cell line showed that hypoxia-induced versican and perlecan mRNA expression were inhibited, 
and this was mediated via HIF signalling. Versican expression was co-regulated by HIF-1α and HIF-
2α but expression of perlecan was influenced only by HIF-1α. Hence oxygen concentration is an 
important modulator of PG expression in macrophages, partially explaining the pro-atherogenic role of 
macrophages in atherosclerotic lesions.120 Furthermore the secreted GAGs from human monocyte-
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derived macrophage (HMDM) exposed to hypoxia, were longer, more sulphated and had a higher 
affinity for LDL compared to those produced under normoxia. These results indicate that hypoxia 
induced changes in macrophage GAG biosynthesis which have important consequences for the 
interaction with LDL and may contribute to the development of atherosclerosis in the hypoxic intima.121 
Within inflamed tissues such as atherosclerotic plaques, macrophages are chronically exposed to 
hypoxic conditions. In stress conditions, such as those associated with inflammation, Akt regulates 
several signalling pathways and mediates cell survival. Macrophages also express metalloproteinases 
(MMP) that promote matrix remodelling and atherosclerotic plaque instability. Whilst moderate 
hypoxia (approximately 2% to 5% O2) does not affect macrophage differentiation (assessed by 
scavenger receptor expression), it was found to be associated with activated Akt and inactivated 
glycogen synthase kinase (GSK)-3 (a negative effector of Akt), allowing nuclear translocation of β-
catenin. Catenin is a transcriptional factor that plays a critical role in a variety of cell processes including 
angiogenesis. Hypoxia was associated with an induction of mRNA expression of the β-catenin-
associated genes, including: MMP-7, CD44, and c-Myc. RNAi of TCF7L2, a cofactor of β-catenin, was 
found to suppress MMP-7 expression induced by hypoxia. Inhibition of Akt phosphorylation by the PI3 
kinase inhibitor, LY294002, abolished hypoxia induced GSK-3 β inactivation, β-catenin activation, and 
MMP-7 expression. Macrophages under hypoxia were found to be more resistant to ox-LDL-induced 
apoptosis. Therefore the induction of macrophage products in chronically hypoxic tissues such as 
atherosclerotic plaques and adipose tissue may further amplify the pro-inflammatory milieu within these 
tissues.122 
Toll-like receptors (TLRs) play an important role in triggering immune and inflammatory responses by 
detecting invading microbial pathogens and endogenous danger signals. They elicit both potentially 
protective and detrimental effects in atherosclerosis where the outcome of TLR signalling is dependent 
on the agonist and responding cell type.123 Increased expression of TLR4 is implicated in exacerbating 
the inflammatory responses in ischemic tissue injury and chronic diseases. TLR4 expression is 
upregulated by hypoxic stress mediated by HIF-1α in macrophages. PI3K/Akt was shown to be 
necessary for HIF-1α stabilization on the early stage of hypoxia through inhibition of GSK-3β. 
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Treatment with pharmacological inhibitors of PI3K and Akt, or knockdown of Akt expression by 
siRNA, were found to block the increase of TLR4 mRNA and protein levels in macrophages exposed 
to hypoxia. Phosphorylation of Akt by hypoxic stress preceded the nuclear accumulation of HIF-1α. 
HIF-1α-mediated up-regulation of TLR4 expression was blocked by LY294002. Furthermore, the 
antioxidant, sulforaphane (SFN) suppressed hypoxia induced up-regulation of TLR4 mRNA and protein 
by inhibiting PI3K/Akt activation and the subsequent nuclear accumulation and transcriptional 
activation of HIF-1α. However, p38 was not involved in HIF-1α activation and TLR4 expression 
induced by hypoxic stress in macrophages. These data indicate that PI3K/Akt contributes to the 
hypoxia-induced increase in TLR4 expression in macrophages at least partly through the regulation of 
HIF-1 activation and that SFN contributes to protection against ischemic tissue injury by down-
regulation of TLR4 expression in macrophages.124 
Inflammation is involved in all phases of atherogenesis, and proinflammatory cytokines and 
chemokines secreted from the immune cells involved in the inflammatory response are involved in the 
progression of the atherosclerotic process.125 Among the cytokines that have received particular 
attention are interleukin-1α (IL-1α) and IL-1β.126 Hypoxia enhances pro-IL-1 β protein, but not mRNA 
expression in lipopolysaccharide (LPS)-stimulated human macrophages. It also retards the autophagic 
degradation of pro-IL-1 β, and thus prolongs its effective half-life, promoting its intracellular 
accumulation. Furthermore, hypoxia increases the expression of NLRP3, and augments caspase-1 
activation in LPS-primed macrophages. Consequently, human macrophages exposed to hypoxia, 
secrete increased levels of mature IL-1 β compared to normoxic macrophages after treatment with 
crystalline cholesterol. In human atherosclerotic plaques, derived from carotid endarterectomy 
specimens, IL-1 β was localized predominantly in macrophage-rich regions that also express activated 
caspase-1 and the hypoxia markers HIF-1α and hexokinase-2. Hence hypoxia appears to potentiate the 
expression of  IL-1 β in the context of atheroma.127 
The link between macrophage glycolysis and their pro-inflammatory activity is probably mediated by 
HIF-1α and the transcriptional induction of 6-phosphofructo-2 kinase, 2, 6-biphosphatase (PFKFB3). 
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Tawkol et al showed that hypoxia could potentiate macrophage glycolytic flux and a proportional up-
regulation of pro-inflammatory activity, that is dependent on both HIF-1α and PFKFB3.128 
In macrophages exposed to hypoxia, there is an up-regulation of several genes, including: VEGF, the 
glucose transporter 1 (GLUT-1), matrix metalloproteinase-7 (MMP-7), neuromedin B receptor, and the 
DNA-binding protein inhibitor. These genes may be important for the survival and functioning of 
macrophages in hypoxic diseased tissues.129 Other immune cells are found within atherosclerotic 
lesions, namely dendritic cells (DCs) and T cells, and are also proposed to contribute to atherogenesis.125 
DCs can be found in healthy arterial vessels but accumulate especially in the areas of atherosclerotic 
plaque. In atherosclerosis, DCs are thought to play an important role in controlling cell recruitment, 
migration, lipid uptake, and T-cell responses. Hypoxia, ox-LDL, tumor necrosis factor-α, and inhibition 
of endothelial NO synthase may all augment adhesion of DC to the endothelium where HIF-1 triggers 
DC activation. 130, 131 
miRNAs are a class of endogenous small RNAs that act as inhibitors of post-translational gene 
expression or promote RNA degradation by duplex-formation within the 3'-UTR of target mRNAs. 
They play an important role during a wide range of cellular processes by fine-tuning gene expression.132 
Monocytes migrate from the circulation, where the oxygen tension is high, into areas with a high 
inflammation, such as the atherosclerotic plaque. There, they differentiate into macrophages. During 
this process there is a change in the expression pattern of the HIF-1α and HIF-2α genes. This is 
associated with a down-regulation of microRNAs encoded by the miR-17-92 cluster. miRNAs from the 
miR-17-92 cluster (mi-17 and -20a), can regulate HIF-1α and HIF-2α by targeting their 3’-UTR. These 
miRNAs are repressed during the differentiation of monocytes into-macrophages. miR-over-expression 
in human macrophages demonstrates the important role of this microRNA-mediated regulation of the 
HIF-system for adaption of macrophages to hypoxia. The HIF-system is activated during the 
differentiation of monocyte into macrophages. This activation is in part mediated by a miRNA-
dependent mechanism, which seems to be crucial for the adaption of macrophages to hypoxia.133 
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2. Animal models  
Rodent models 
a. Altering HIF-1 expression  
HIF-1α is the regulatory subunit of a transcriptional complex, which controls the recruitment of 
multipotent progenitor cells and tissue repair in ischemic tissue by inducing stromal cell- derived factor 
(SDF)-1 α expression. In VSMCs, HIF-1α can be activated under normoxic conditions by platelet 
products. Previous studies have investigated the effect of altering the local expression of HIF on 
atherosclerotic plaque development in murine vascular injury models. 
The expression of HIF-1α has been investigated in a wire-induced vascular injury model in the 
hyperlipidaemic ApoE(-/-) mice. In this model, HIF-1α expression was increased in the tunica media, 
predominantly in the SMCs, as early as 1 day after injury. Nuclear translocation of HIF-1α and co-
localization with stromal cell derived factor (SDF-1α; a pro-inflammatory chemokine upregulated in 
injured vessels and responsible for cell migration and recruitment of new smooth muscle progenitor 
cells) was detected in neo-intimal cells after 2 weeks. HIF-1α mRNA expression was induced at 6 hours 
after injury as determined by real-time RT-PCR. Inhibition of HIF-1α expression by local application 
of HIF-1α-siRNA reduced the neo-intimal area by 49% and significantly decreased the neo-intimal 
SMCs content compared to treatment with the control- siRNA. The expression of HIF-1α and SDF-1α 
were reduced in neo-intimal cells of the HIF-1α-siRNA treated arteries. HIF-1α expression therefore 
appears to be directly involved in the formation of the neo-intimal after vascular injury and mediates 
the up-regulation of SDF-1α, which may affect the stem cell-dependent repair of injured arteries.134 In 
experiments in which the local expression of the different HIF-subunits (HIF-1α, HIF-2α) was increased 
using adenoviral infection, or reduced by using a dominant-negative mutant, the extent of neo-intima 
formation was reduced in the dominant negative mutant mice, and this was associated with decreased 
expression of several established HIF-target genes, including: VEGF-A and its receptors Flt-1 and Flk-
1. In contrast, the local overexpression of HIF-1α and HIF-2α was associated with a further increase in 
the injury induced neo-intima formation.135 
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HIF-1 is detectable in the nuclei of endothelial cells (ECs) covering murine and human atherosclerotic 
lesions. When the HIF-1α gene was specifically deleted in the ECs from ApoE knockout mice (EC-
HIF-1α (-/-)), the degree of atherosclerotic lesions, the lesional content of macrophages, and the 
expression of CXCL1 (responsible for the accumulation of macrophages in the atherosclerotic lesion) 
in ECs were all reduced in the lesions produced by partial ligation of the carotid artery or in the aorta 
following diet-induced atherosclerosis in EC-HIF-1α (-/-) compared with control mice. In parallel in 
vitro studies, it was reported that mildly ox-LDL or lysophosphatidic acid 20:4 increased endothelial 
CXCL1 expression and monocyte adhesion in the atherogenic lesion via the induction of HIF-1. In the 
mice with endothelial HIF-1α deficiency there was a down-regulation of the micro RNA miR-19a, 
which controls endothelial function and neo-vascularization; and HIF-1-induced miR-19a expression 
that mediated the up-regulation of CXCL1 in mildly ox-LDL-stimulated ECs.136 
HIF-1 has also been reported to attenuate the inflammatory response by regulating T cell activation and 
cytokine production. When HIF-1α was over-expressed in ApoE knockout murine lymphocytes, 
antibody array analysis revealed a pattern consistent with a shift in the cytokine translation pattern from 
a T helper 1 to T helper 2 phenotype. Normally, the mice in this model develop atherosclerotic lesions 
within the aortic sinus and these lesions were reduced in the mice with T cells over-expressing HIF-1α. 
These findings were associated with a reduced expression of IFN-gamma in CD4+ spleen-derived 
lymphocytes and aortae of these mice representing a novel immune-modulatory approach in 
atherosclerosis.137 
It has been also reported that HIF-1 expression is upregulated in CD11c(+) antigen presenting cells 
(APCs) within atherosclerotic plaques of LDL receptor-deficient (Ldlr(-/-)) mice and that conditional 
deletion of HIF-1α in CD11c(+) APCs in high-fat diet-fed Ldlr(-/-) mice increased the formation of 
atherosclerotic plaques, and increased lesional T-cell infiltration. This suggests HIF-1 has a protective 
role during atherogenesis. It was further reported that HIF-1 directly modulates Signal Transducers and 
Activators of Transcription 3 (Stat3). A reduction in STAT3 expression was found in HIF1-deficient 
APCs and aortic tissue, together with an upregulated interleukin-12 expression and expansion of type 
1 T-helper (Th1) cells. Over-expression of STAT3 in bone marrow cells of HIF-1α-deficient APCs 
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reversed the enhanced atherosclerotic lesion formation and reduced Th1 cell expansion in chimeric Ldlr 
(-/-) mice. Furthermore, deletion of HIF-1α in the lysine motif; LysM (+) bone marrow cells (the most 
prominent motif for binding to peptidoglycans) in Ldlr (-/-) mice, did not affect lesion formation or T-
cell activation. In human atherosclerotic lesions, HIF-1, STAT3, and interleukin-12 protein were found 
to co-localize with APCs. HIF-1 therefore appears to inhibit APC activation and Th1 T-cell polarization 
during in Ldlr(-/) mice and to attenuate the progression of atherosclerosis.138 
Vascular injury can be induced by placement of an external vascular polyethylene cuff, which is 
associated with the formation of a neo-intima.139 When this model of vascular injury was used in HIF-
1-(T-cell)-deficient mice, there was an enhanced neo-intimal response in the mutant mice, and 
significantly greater infiltration of inflammatory cells into the adventitia. The authors suggest that the 
mechanism of augmented vascular remodelling in the mutant mice appeared to be due to enhanced 
production of cytokines by activated T cells and increased antibody production in response to a T-
dependent antigen in the mutant mice.140 
Using an ex-vivo rat tail artery model maintained for 4 days in hypoxic or normoxic culture and then 
assessed for contractility, oxygen consumption, and lactate production in oxygenated medium, hypoxia 
was found to be associated with depressed basal energy turnover, impaired mitochondrial capacity, and 
altered Ca2+ homeostasis, but did not affect contractile energetics.141 
b. Intermittent Hypoxia 
As discussed earlier in the review, intermittent hypoxia (IH) is a feature of obstructive sleep apnoea 
(OSA), and is associated with increased cardiovascular mortality and pulmonary hypertension. This 
may be attributable either to more extensive lesions, or lesions that are more unstable in subjects with 
OSA. In a murine model of IH, using a quantitative proteomic method showed that a total of 163 
proteins were identified as having changed significantly, of which 34 showed significant differences 
between genders, and which may be related to vascular injury induced by chronic IH. Twenty up-
regulated proteins and 14 down-regulated proteins were observed in female mice compared to male 
mice.142 
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When ApoE-deficient (ApoE(-/-)) mice were fed on a high cholesterol diet, and then subjected to IH 
for up to 12 weeks, it was reported that at 4 weeks, IH was associated with an increased plaque size in 
the aortic sinus and the descending aorta. At 12 weeks, atherosclerosis progressed in all groups, but 
more rapidly in the descending aorta of the IH-exposed animals. Plaque composition was similar 
between IH and controls. In the mice exposed to IH, blood pressure rose with time compared to the 
mice kept in normoxia, and there were relatively stable increases in serum lipids and arterial stiffness.143 
Intermittent hypoxia may cause endothelial dysfunction in part by the local increase in ROS and 
reduction of the peripheral repair capacity. This is supported by the finding that anti-inflammatory; 
Infliximab and anti-oxidant; L-glutathione prevent hypoxia-induced vascular and extravascular 
changes.144 
The hormone adiponectin has been reported to have anti-atherosclerotic properties. Severe obstructive 
sleep apnoea-hypopnea syndrome (OSAS) is associated with hypo-adiponectinemia and a nocturnal 
reduction in circulating adiponectin concentrations. Exposure of mice to 3-weeks of sustained hypoxia 
(10% O2) resulted in a significant accumulation of adiponectin in the pulmonary arteries. Pulmonary 
arterial wall remodelling, was found to be greater in adiponectin-knockout mice than wild-type mice 
under hypoxia. Over expression of adiponectin was associated with significantly decreased hypoxia-
induced pulmonary arterial wall thickening and right ventricular hypertrophy.145 In rats exposed to IH 
for 8 hours/day, for 5 weeks, cardiac dysfunction was induced as measured by echocardiograph. 
Adiponectin treatment was associated with amelioration in these indices of cardiac dysfunction and also 
reduced expressed proteins associated with endoplasmic reticulum (ER) stress as well as the expression 
of ROS.146 
ApoE-KO mice, and mice deficient in both ApoE and p50 genes (ApoE-p50-DKO), were exposed to 
IH or sham conditions. IH caused atherosclerosis in ApoE-KO mice fed on a normal chow diet in a 
time-dependent manner. IH caused more severe atherosclerotic lesions in the ApoE-p50-double KO 
(DKO) mice on a normal chow diet. ApoE-KO and ApoE-p50-DKO mice exposed to IH for 30 and 9 
weeks, respectively, displayed similar areas of atherosclerotic lesions on cross sections of aortic root. 
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P50 gene deletion (in ApoE-p50-DKO mice) significantly augmented IH-induced serum levels of 
tumour necrosis factor-α and IL-6, aortic tumour necrosis factor-α, and inducible NOS expression and 
aortic infiltration of Mac3-positive macrophages (a marker of proliferation). IH caused a greater 
elevation in serum cholesterol concentrations in ApoE-p50-DKO than in ApoE-KO mice. IH was found 
to be associated with a down-regulation of hepatic LDL receptor and HMG-CoA reductase expression 
in the ApoE-p50-DKO but not in ApoE-KO mice. NF-κB p50 appeared to protect against IH-induced 
atherosclerosis by inhibiting vascular inflammation and hypercholesterolemia.147 
In male ApoE-deficient mice subjected to intermittent hypobaric hypoxia (IHH) for 8 weeks for 8 hours 
a day, plasma lipid levels, and plaque size did not differ from control mice. However, the IHH-treated 
mice exhibited significantly decreased plaque collagen content, and increased matrix metalloproteinase 
(MMP)-9 protein expression; both features of atherosclerotic plaque instability. Tissue inhibitor of 
MMP (TIMP)-2 expression was decreased after exposure to IHH. Hence, IHH may promote 
atherosclerotic plaque instability in ApoE-deficient mice by changing the balance of MMPs and 
TIMPs.148 In order to explore the early impact of IH on endothelial function and atherogenesis, ApoE-
/- mice were exposed to a 6-week-intermittent hypoxia either immediately (early pre-atherosclerosis) 
or after 5 weeks of high-cholesterol diet (advanced pre-atherosclerosis), with mice maintained under 
normoxia serving as controls. Endothelial function was assessed ex vivo. Flow cytometry was used to 
assess blood plasma CD31+/ annexin V+ endothelial micro-particles as well as sca1/flk1+ endothelial 
progenitor cells in blood and bone marrow. IH was found to cause impaired endothelial function and 
integrity. Peripheral repair capacity expressed as the number of endothelial progenitor cells in blood 
was attenuated under IH, despite the elevated number of these cells in the bone marrow. In contrast, 
endothelial function, as well as micro-particle and endothelial progenitor cell levels were similar under 
IH versus control in more advanced pre-atherosclerosis.149  
When endothelial cells were co-cultured with lymphocytes isolated from rats that had been subjected 
to either IH, or normal conditions, there was a significant decrease in apoptosis regulators, Bcl-2 level 
and the Bcl-2/Bax ratio, and a significant increase in apoptosis as assessed by Bax and caspase-3, and 
an increase in measures of oxidative stress (MDA, SOD, and CAT) and inflammation (TNF-α, IL-8, 
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CRP, and ICAM-1). These effects were partially restored by pre-treatment with tempol (a membrane 
permeable free radical scavenger) and exacerbated by intermittent hypoxic co-incubation.150 
Supplementation with the n-3 polyunsaturated fatty acid, docosahexanoic acid (DHA) which has anti-
inflammatory properties, prevented IH-induced atherosclerosis acceleration in ApoE -/- mice. This was 
associated with a decrease in aortic MMP-2 gene expression.151  
c. Miscellaneous hypoxia-related studies in Murine models 
Whilst advanced murine and human plaques are hypoxic it is unclear whether plaque hypoxia is causally 
related to atherogenesis. It is possible to partially ameliorate the hypoxia in atherosclerotic plaques by 
breathing hyperoxic carbogen gas. LDL receptor-deficient mice (LDLR-/-), fed on a Western-type diet, 
were treated with carbogen (95% O2, 5% CO2) or air, and the effect on plaque hypoxia size, and 
phenotype was studied. Pimonidazole was used as an indicator of tissue hypoxia. Carbogen increased 
arterial blood pO2 5-fold and reduced plaque hypoxia in advanced plaques of the aortic root and arch. 
The effect of repeated carbogen exposure on atherosclerosis in LDLR-/-mice fed on a Western-type 
diet included: a reduction in plaque hypoxia (-40%), necrotic core size (-37%), and TUNEL+ (terminal 
uridine nick-end labeling positive) apoptotic cell content (-50%) and increased efferocytosis of 
apoptotic cells by cluster of differentiation 107b+ (CD107b, MAC3) macrophages (+36%) in advanced 
plaques of the aortic root. Plaque size, plasma cholesterol, hematopoiesis, and systemic inflammation 
were unchanged. In vitro, hypoxia hampered efferocytosis by bone marrow-derived macrophages.152 
Following a myocardial infarction there is a mobilization of endothelial progenitor cells (EPCs) from 
the bone marrow. This appears to be affected by the circadian gene period2 (per2) that is known to 
regulate the function of EPCs. Flow cytometry revealed a decreased number of circulating EPCs in 
per2(-/-) mice after MI. In vitro, per2(-/-) EPCs showed decreased migration and tube formation 
capacity under hypoxia. Western blot analysis revealed that there was an inhibition in the activation of 
extracellular signal-regulated kinase and Akt signaling in the bone marrow of per2(-/-) mice and 
inhibited PI3K/Akt expression in per2 (-/-) EPCs under hypoxia.153 
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A number of microRNAs function as tissue protective factors in ischemia-reperfusion (I/R) and/or 
hypoxia-reperfusion (H/R)-induced myocardial injury. miR-21 has an anti-apoptotic role in I/R-induced 
myocardial damage in vivo and in H/R-induced H9C2 cell death in vitro. Increased expression of miR-
21 upregulates Akt signalling activity by suppressing the expression of phosphatase and tensin homolog 
(PTEN; an Akt negative regulator) and the increased activity of Akt signalling further inhibits apoptosis 
partially by increasing the ratio of B-cell lymphoma 2(Bcl-2)/Bcl-2-associated X protein, which further 
suppressed the expression of caspase-3. Hence miR-21 has a protective role in I/R- and H/R-induced 
cardiocyte apoptosis via the PTEN/Akt-dependent mechanism.154 
Rabbit models 
The presence of hypoxia within atherosclerotic lesions has been confirmed using 7-(4'-(2-nitroimidazol-
1-yl)-butyl)-theophylline (NITP) which binds to foam cells in cholesterol-fed rabbits.24 
Removal of the carotid artery adventitia from rabbits can induce the formation of an intimal hyperplastic 
lesion. In rabbits fed on a normal diet, the size of the lesion (measured as the intimal: medial ratio) was 
maximal by day 14 and thereafter, regressed toward control dimensions by day 28. In rabbits fed on a 
high cholesterol (HC) diet, the lesion was again maximal by day 14. Although some regression was 
seen, the lesion persisted to day 42. The authors proposed that lesion formation may be initiated 
following the development of arterial wall hypoxia, secondary to excision of the adventitial vasa 
vasorum.155 
Micro-angiogenesis in the arterial wall has been observed during the development and progression of 
atherosclerosis. The inter-relationship between inflammation, oxidative stress and hypoxia has been 
investigated with respect to the process of early atherosclerotic micro-angiogenesis in the cholesterol-
fed rabbit. The microvessel density (MVD) in the HC group was significantly higher (P<0.01) than that 
observed in the normo-cholesterolemic rabbits. Whilst HIF-1α levels did not change significantly in 
either of the two groups the levels of inflammatory markers and antioxidants were significantly different 
between the two groups (P<0.05). These results suggest that during the initial stages of the 
hyperlipidemia-induced atherosclerosis, micro-angiogenesis may be associated with an increase in 
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inflammation and a decrease in the levels of antioxidants which promote this process even before any 
tissue hypoxia is detected.1 
Ex vivo, organ bath experiments show that segments of aortae from control, cholesterol-fed, or 
Watanabe hereditary hyperlipidemic (WHHL) rabbits have substantially different responses when the 
experiments were conducted in hypoxic versus normoxic conditions. These experiments looked at 
responses to: aggregating platelets, 5-hydroxytryptamine (serotonin; 5-HT), norepinephrine, 
endothelin, and prostaglandin F2α. The contractions under hypoxic conditions in the atherosclerotic 
rings were not dependent on the presence of an intact endothelium as they could not be antagonized by 
blockers of α-adrenoceptors, 5-HT2 receptors, histamine receptors, thromboxane receptors, and 
muscarinic cholinoreceptors. Inhibitors of cyclooxygenase, lipoxygenase, Na+, K+-ATPase, and free 
radical scavengers or an activator of endothelium-derived relaxing factor did not significantly affect the 
hypoxic contraction. The absence of effect of several inhibitors of protein synthesis appears to rule out 
the involvement of endothelin, angiotensin II, and bradykinin. The contraction under hypoxic 
conditions was not influenced by the omission of Ca2+ from the medium or by inhibition of Ca2+ influx 
but was prevented by blockade of intracellular Ca2+. The inhibitors of NOS (nitro-L-arginine, 100 µM) 
and the guanylyl cyclase (methylene blue, 10 μM) both enhanced the initial contractile responses to 5-
HT to a similar extent as hypoxia and completely prevented the hypoxic contraction in the 
atherosclerotic tissues. Hypoxia decreased cGMP but not the cAMP levels in atherosclerotic aortae with 
and without endothelium. These data indicate that there are unusual vasoconstrictor responses in 
atherosclerotic arteries; this constrictor response depends on the availability of intracellular Ca2+ and 
seems to be due to the further inhibition of an already impaired cGMP production, most likely due to 
inhibition of NOS present in non-endothelial cells of the atherosclerotic blood vessels.156 
Balloon injury in the iliac-femoral arteries of hypercholesterolaemic rabbits fed with a 0.5% cholesterol 
diet or a conventional diet was used as a model of atherosclerosis in which macrophage-rich or a smooth 
muscle cell (SMC)-rich neo-intima was created. Several metabolites of the glycolytic and pentose 
phosphate pathways (an alternative route of glucose catabolism) were found to be increased, and the 
tricarboxylic acid (TCA) cycle in the iliac-femoral arteries with macrophage-rich neo-intima, compared 
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with those that were not injured and those with SMC-rich neo-intima. Pimonidazole immunoreactivity 
was closely localized with the nuclear translocation of HIF-1α and hexokinase II expression in 
macrophage-rich neo-intima. In vitro, THP-1 macrophages stimulated with lipopolysaccharides (LPS) 
and interferon-gamma (IFN- γ) were cultured under normoxic and hypoxic conditions. The levels of 
glycolytic and pentose phosphate pathway (4 of 6) metabolites increased in LPS and IFN- γ stimulated 
macrophages under hypoxic but not normoxic condition.157 
Whilst it has been reported that hypoxia increases, and hyperoxia reduces experimental atherosclerosis, 
it is unclear if repetitive hypoxic and hyperoxic insults affect intimal thickening after arterial injury. In 
a rabbit model of intermittent repetitive hypoxia or hyperoxia, hypoxia markedly increased the intima-
to-media ratio in the abdominal aorta (AA) whereas hyperoxia had no effect on AA disease but 
increased intimal thickening in thoracic aorta (TA). Hyperoxia promoted positive arterial re-modelling 
in both TA and AA, resulting in larger luminal size. The cholesterol content in AA was increased by 
hypoxia and decreased by hyperoxia, but decreased by both treatments in TA. Lipophilic antioxidants 
and the proportion of arterial lipids that was oxidized were not altered by either hypoxia or hyperoxia. 
Hence, intermittent repetitive hyperoxia is not protective but promotes arterial disease in normal and 
injured arteries independent of lipid peroxidation.158 
Porcine models 
In Yucatan miniature pigs the oxygenation profiles across the superficial femoral arteries has suggested 
a relatively poorly oxygenated media (a trough value of approximately 25% of the intimal oxygenation 
has been reported) with a progressive rise in oxygenation toward the intimal and adventitial surfaces. 
The vasa vasorum are required to supply the outer media with oxygen, and occlusion of the adventitial 
vasa vasorum by flush ligation of the arterial branches that supply them resulted in a focal, intimal 
hyperplastic lesion, composed predominantly of smooth muscle cells which have migrated from the 
media or was a product of some migration that resulted in proliferation; a process initiated by hypoxia. 
21 
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Coronary arteries also contain a network of adventitial vasa vasorum. These have been visualized in the 
cholesterol-fed pig, using a novel computed tomography technique. Two different types of vasa 
vasorum were defined: first-order vasa vasorum ran longitudinally parallel to the vessel and second-
order originated from first-order vasa vasorum circumferentially around the vessel wall. In the 
hypercholesterolemic coronary arteries, there was a significant increase in the area of the vessel wall 
and in the density of vasa vasorum. The latter occurred especially by an increase of second-order vasa 
vasorum and was associated with a loss of the normal spatial pattern. Hence adventitial neo-
vascularization of the vasa vasorum occurs in experimental hypercholesterolemic coronary arteries 
before the development of vascular lesion. This occurs particularly by an increase of second-order vasa 
vasorum and a loss of orientation of the normal vasa vasorum pattern, which may be a part of the early 
atherosclerotic remodelling process.159 
3. Ex Vivo human studies 
Markers of hypoxia and inflammation have been previously identified by microarray analysis, in 
atherosclerotic carotid arteries with low to moderate stenosis. A notable overexpression of HIF-1α in 
inflammatory and hypoxic areas of carotid arteries in all types of lesions (type II-V lesions) taken from 
patients with carotid stenosis of < 50% was found.160 
Heat shock proteins (HSPs) are molecular chaperones which are essential for cell survival.161 Hypoxia 
was reported to markedly increase the expression of several HSPs in human saphenous vein and the 
internal mammary artery from patients undergoing coronary artery bypass surgery. A 6 h period of 
oxygen deprivation resulted in elevated levels of HSP60, and HSP72 and of HSP73 in the saphenous 
vein. In the internal mammary artery, HSP73 expression was found to be significantly enhanced.162 
The precise cellular and molecular mechanisms regulating adventitial vasa vasorum neo-
vascularization, which occurs in the pulmonary arterial circulation in response to hypoxia, remain 
unknown. In the vessel wall, endothelial cells and mural cells, including fibroblasts, pericytes, and 
smooth muscle cells, make physical cell-cell contacts, suggesting a role for intracellular communication 
in the regulation of vascular growth and function.  The cell-cell communication between endothelial 
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cells and non- endothelial cells may represent a critical process in the initiation, stabilization, and 
maturation of new vessels. Adventitial fibroblasts (AdvFBs) and vasa vasorum endothelial cells 
(VVECs) were isolated from the adventitia of pulmonary arteries. Hypoxia activated pulmonary artery 
AdvFBs exhibited pro-angiogenic properties and influenced the angiogenic phenotype of the VVEC, in 
a process involving endothelin-1 (ET-1); a pro-angiogenic regulator of neo-vascularization in many 
pathological conditions. AdvFBs, either in experiments using co-culture, or conditioned media, 
stimulated VVEC proliferation or augmented the self-assembly and integrity of cord-like networks that 
formed when VVECs where cultured on Matrigel. When co-cultured on Matrigel, AdvFBs and VVECs 
self-assembled into heterotypic cord-like networks, a process augmented by hypoxia but attenuated by 
either selective endothelin receptor antagonists or oligonucleotides targeting prepro-ET-1 mRNA. 
Hence hypoxia-activated AdvFBs exhibit pro-angiogenic properties and communicate with VVECs, in 
a process involving ET-1, to regulate vasa vasorum neo-vascularization occurring in the adventitia of 
pulmonary arteries in response to chronic hypoxia.163 
Increased HIF-1α expression is observed in human atherosclerotic plaque with different phenotypes. 
The expression of HIF-1α appears to be associated with the presence of a large extracellular lipid core 
and macrophages and co-localizes with VEGF. HIF-1α is also associated with an inflammatory 
phenotype and with VEGF expression. HIF-1α expression is upregulated in activated macrophages 
under normoxic conditions suggesting that plaque (immune) inflammatory reactions might also be 
involved in plaque HIF-1α expression.164 Intra-plaque angiogenesis is a typical feature of hypoxic tissue 
and expression of HIF. Sluimer et al. have demonstrated the presence of hypoxia in human advanced 
atherosclerotic lesions. Hypoxia was assessed by infusing pimonidazole before carotid endarterectomy. 
The mRNA and protein expression of HIF-1α, HIF-2α, HIF-responsive genes (VEGF, glucose 
transporter [GLUT]1, GLUT3, hexokinase [HK]1, and HK2), and microvessel density were determined 
in a series of non-diseased and atherosclerotic carotid arteries using microarray, quantitative reverse 
transcription polymerase chain reaction, in situ hybridization, and immunohistochemistry. 
Pimonidazole immune-histochemistry showed hypoxia was particularly present within the macrophage-
rich core of the lesions and correlated with the presence of angiogenesis, thrombus formation, and 
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expression of CD68, HIF, and VEGF. The mRNA and protein expression of HIF, its target genes, and 
microvessel density increased from early to stable lesions, but no changes were observed between stable 
and ruptured lesions. The HIF pathway was associated with lesion progression and angiogenesis, 
suggesting its involvement in the response to hypoxia and the regulation of human intra-plaque 
angiogenesis.165 
OSA is known to be a risk factor for coronary heart disease. Peripheral blood was taken from adults 
with suspected OSA and mRNA was prepared from the isolated monocytes for the analysis of C-C 
chemokine receptor 2 (CCR2; a chemokine that mediates monocyte chemotaxis). Monocytic CCR2 
gene expression was found to be increased in severe OSA patients and higher levels were detected after 
sleep. In vitro experiments showed that IH increased the CCR2 expression in THP-1 monocytic cells 
even in the presence of TNF-α and CRP and also promoted the monocyte chemotactic protein-1 (MCP-
1)-mediated chemotaxis and adhesion of monocytes to endothelial cells. Both ERK and p38 MAPK 
were confirmed to be involved in the signalling pathway for the induction of CCR2 in monocytes by 
IH. These results strongly suggest an important role of CCR2, in atherosclerosis in patients with OSA.166 
Neuro-immune guidance cue netrin-1 (Ntn1), initially characterized in the specialized migration of 
neurons during development, has also been found to inhibit macrophage migration from atherosclerotic 
plaques, and hence enhances chronic inflammation. Netrin-1 and its receptor uncoordinated-5-B 
receptor (Unc5b) are expressed in macrophages in hypoxic regions of human and mouse plaques. Ntn1 
and Unc5b mRNA are also upregulated in macrophages treated with ox-LDL or inducers of oxidative 
stress, including hypoxia. These responses are abrogated by inhibiting HIF-1α, indicating a causal role 
for this transcription factor in regulating Ntn1 and Unc5b expression in macrophages. J774 
macrophages overexpressing active HIF-1α express increased levels of netrin-1 and Unc5b and have a 
reduced migratory capacity compared with control cells. This can be restored by blocking the effects of 
netrin-1. Netrin-1 protects macrophages from apoptosis under hypoxic conditions in a HIF-1α-
dependent manner via regulating macrophage trafficking and accumulation during hypoxia in 
atherosclerosis. Therefore, HIF-1α regulation of netrin-1 is involved in promoting macrophage 
accumulation and survival in atherosclerotic plaque and provides further evidence of a role for hypoxia 
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in sustaining inflammation. Local inhibition of such factors may have a therapeutic value for the 
resolution of inflammation in atherosclerosis and other chronic inflammatory disease.167, 168 A high 
proportion of stable plaques have been reported to have neo-vascularization. Regional expression of 
hypoxia- and thioredoxin- related genes in different parts of stable atherosclerotic carotid plaques has 
been investigated. The expressions of HIF-lα, VEGF-A, thioredoxin, and thioredoxin interacting protein 
were analysed in carotid endarterectomy samples using RT-PCR on laser micro-dissected regions. The 
expression of all four genes was significantly lower in the medial region at the mRNA level. High 
expression of these genes was noted in the shoulder region and sites of neo-vascularization, with no 
significant difference between the two, and these expression patterns were related to macrophage 
infiltration. Hypoxia- and thioredoxin-related genes are significantly overexpressed in human stable 
carotid atherosclerotic plaques and strongly correlate with macrophage infiltration rather than neo-
vascularization. Macrophage infiltration may lead to overexpression of these genes providing a 
mechanism of transcriptional activation of several other target genes contributing to angiogenesis, 
atherosclerotic progression and vascular remodelling in stable carotid plaques.169 
Plaque haemorrhage in carotid atherosclerosis may promote plaque progression, and rupture that may 
result in cerebrovascular disease. HIF-1α induces angiogenesis via the expression of VEGF and E26 
transformation-specific-1 (Ets-1). A higher incidence of plaque haemorrhage is observed in plaques 
associated with symptoms than in those without. HIF-1 α, VEGF, and Ets-1 expression is co-located in 
the deep layer of plaque, where angiogenesis is also well developed.  Symptomatic plaques were found 
to have a higher expression of VEGF than asymptomatic plaques. Plaques with haemorrhage were 
associated with a higher incidence of plaque ulceration and higher expression of Ets-1 than those 
without haemorrhage. Significantly higher expression levels of VEGF and Ets-1 were observed in 
plaques with haemorrhages, ulcers and severe stenosis. Hypoxia-inducible angiogenic proteins in 
human carotid atherosclerosis therefore appear to promote intra-plaque angiogenesis, which can induce 
plaque haemorrhage and progression.170 
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Genetic determinants of the response to Hypoxia 
Patients with chronic ischemic heart disease develop coronary artery collaterals (new vessels) due to 
myocardial hypoxia. However, there is a marked variability in the tendency to develop these collaterals. 
Whilst this variability is likely to be multifactorial, genetic factors are thought to be involved. Genetic 
variations in HIF-1α has been reported to influence the development of coronary artery collaterals in 
patients with significant coronary artery disease.171 They have also been reported as predisposing to 
abdominal aortic aneurysm.172 
Conclusions 
There is now substantial evidence that there are areas of profound hypoxia within atherosclerotic 
lesions. There is also good evidence that hypoxic states, such as that associated with obstructive sleep 
apnoea may be involved in the aetiology of cardiovascular disease. HIF-1 appears to be an important 
mediator of the pro-atherogenic cellular response to hypoxia. Hypoxia has important effects on 
intermediary metabolism, cholesterol disposal and the inflammatory response within the artery wall. It 
also appears to promote changes in the cellular and extracellular composition of the artery wall that may 
impact on the response to injury. 
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